Pharmaceutical Benefit Plan Settlements
$100 Million available via Pharmaceutical Benefit Plan Settlements
Overview
There are typically several active lawsuits and/or class action settlements that fall into the category of “pharmaceutical benefit plan settlements.” Under these cases, it is generally alleged that businesses with self-insured health plans overpaid for drugs purchased on behalf of their employees due to artificially inflated and/or stabilized prices.
The prices were allegedly manipulated as a result of anti-competitive practices undertaken by the drug manufacturers. The number of these opportunities in any given year varies, but there can be several available at the same time.
Immediately Available Settlement(s):
Zetia Settlement
Date Range: November 2014 - November 2019
Settlement Fund: $70 million
Filing Deadline: 8/7/2023
Settlement Overview: This settlement resolves allegations the Defendants entered into an unlawful reverse-payment settlement agreement to delay the generic launch of Zetia (a drug for lowering cholesterol), which prevented the class from gaining access to lower-priced generic Zetia.
Eligible Locations: To be a member of the Settlement Class, you must have indirectly purchased, paid and/or provided reimbursement for some or all of the purchase price of brand Zetia or its AB-rated generic equivalents in any form, that was sold through a retail pharmacy, including mail-order pharmacies and long-term care pharmacies in Select States.
Select States: Alabama, Arizona, California, District of Columbia, Florida, Hawaii, Illinois, Iowa, Kansas, Maine, Michigan, Minnesota, Mississippi, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, Puerto Rico, Rhode Island, South Dakota, Tennessee, Utah, Vermont, Virginia, West Virginia, and Wisconsin.
Eligible Drugs: Brand or generic Zetia.
Exforge Settlement
Date Range: September 2012 - June 2018
Settlement Fund: $30 million
Filing Deadline: 8/18/2023
Settlement Overview: A settlement fund for end payors has been created to resolve allegations Defendants conspired to delay the release of the less expensive generic version of Exforge (used to treat high blood pressure) from entering the market.
Eligible Locations: To be a member of the Settlement Class, you must have indirectly purchased, paid and/or provided reimbursement for some or all of the purchase price for brand or generic Exforge, in Select States.
Select States: the District of Columbia, Arizona, California, Florida, Hawaii, Iowa, Maine, Michigan, Minnesota, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, South Dakota, Utah, Vermont, West Virginia, and Wisconsin.
Eligible Drugs: Branded Exforge and Generic Exforge (Fixed Combination of Amlodipine and Valsartan tablets).
Recommended Next Steps Data is often required to complete your claim for settlements in this category. Connect us with a member of your Benefits Department so an MCAG representative can describe the information that is necessary to complete your claim for these pharmaceutical settlements. We typically only need a 5 to 10 minute call. We will quickly review the process so we can efficiently obtain necessary information from your Pharmacy Benefit Manager (i.e. CVS Caremark, Express Scripts, OptumRX) to pursue current and future pharmaceutical settlements.
Eligible contracted clients can expect to be contacted by an MCAG representative to review and assist with gathering the necessary information for these settlements.
MCAG is not the Settlement/Class Administrator, and this is not an official settlement website.
Need more information? CLICK HERE to complete our contact form and an MCAG representative will respond shortly.